|
5/9/2013 6:29:37 AM
|
|
|
5/9/2013 6:04:16 AM
|
Trevena And Forest Labs Announce Collaborative Agreement For Development Of TRV027 For Acute Heart Failure
|
|
5/2/2013 4:29:33 AM
|
|
|
5/2/2013 4:18:03 AM
|
Forest Labs, Almirall Unveil Positive Results For Second Phase III Study For LAMA And LABA Combination In COPD
|
|
5/1/2013 3:59:59 PM
|
|
|
5/1/2013 2:18:25 PM
|
Forest Laboratories, Almirall Announce Positive Results From AUGMENT COPD
|
|
4/23/2013 9:00:53 AM
|
|
|
4/23/2013 7:36:38 AM
|
|
|
4/23/2013 7:01:26 AM
|
Forest Laboratories Posts Q4 EPS Of $0.17 Vs. $0.72 Prior Year
|
|
4/19/2013 4:43:26 PM
|
Barclays Capital Is Cutting Forest Laboratories Inc (FRX) FY14 Estimate To 0.76 From 1.37
|
|
4/19/2013 4:42:58 PM
|
Barclays Capital Is Cutting Forest Laboratories Inc (FRX) FY13 Estimate To 0.24 From 0.41
|
|
4/18/2013 9:03:35 AM
|
|
|
4/16/2013 9:40:59 AM
|
Almirall, Forest Labs Report Positive Results Of Phase III Study For Aclidinium And Formoterol Combination In COPD
|
|
4/16/2013 3:24:39 AM
|
|
|
4/16/2013 2:33:09 AM
|
Forest Labs, Almirall Unveil Positive Phase III Study Results For Aclidinium/Formoterol Combination In COPD
|
|
1/17/2013 8:19:16 PM
|
|
|
1/17/2013 5:07:06 PM
|
|
|
1/17/2013 5:00:44 PM
|
Forest Laboratories Announces Health Canada Approval Of BYSTOLIC For Treatment Of Hypertension
|
|
1/15/2013 9:00:38 AM
|
|
|
1/15/2013 8:45:34 AM
|
|